查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1835361

腹腔内感染疾病市场（按抗生素类别、感染类型、病原体类型、患者年龄层和最终用户划分）—2025-2032 年全球预测

Intra-abdominal Infections Market by Antibiotic Class, Infection Type, Pathogen Type, Patient Age Group, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，腹腔内感染疾病市场将成长 497 亿美元，复合年增长率为 9.20%。

主要市场统计数据
基准年2024年 245.7亿美元
预计2025年 268.6亿美元
预测年份：2032年 497亿美元
复合年增长率（%） 9.20%

腹腔内感染疾病种类繁多，从简单的局部发炎过程到复杂的、危及生命的多菌性脓毒症，不一而足。临床医生面临社区获得性感染和医院获得性感染的混合感染，这些感染的来源、宿主因素和微生物学各不相同。因此，早期发现和及时控制感染源仍然是有效管理的基础，抗生素的选择必须在经验性扩大用药量和根据培养和药敏数据逐渐减量之间取得平衡。

诊断的复杂性源自于重迭的临床表现、差异化的培养产量以及不断变化的抗药性模式。影像学检查、手术评估和腹膜培养至关重要，但每种检查都存在局限性，会影响治疗时机。同时，主要病原体中的抗菌药物抗药性正在改变经验性治疗方案，促使重症病例依赖更高级的药物和组合方案。这些变化促使人们需要协调一致的抗菌药物管理、多学科治疗途径和强有力的医院监测，以保留治疗方法方案并优化治疗结果。

因此，临床、营运和商业领域的相关人员必须在及时诊断、综合管理和供应链连续性等优先事项上达成一致。透过了解推动治疗决策的临床细微差别和系统压力，领导者可以更好地设计干预措施，以降低发病率、缩短住院时间，并限制不必要的广谱抗生素暴露带来的附带危害。

快速变革正在改变腹腔内感染管理的临床、诊断和给药动态

由于抗菌药物抗药性、技术进步和医疗服务模式的转变，腹腔内感染管理模式正在发生快速且显着的变化。抗药性趋势正在重塑经验性处方模式，并提升了那些对多重抗药性革兰氏阴性菌具有活性的药物的临床和经济价值。同时，快速诊断和分子病原体检测的创新正在缩短从就诊到标靶治疗的间隔时间。

医疗保健服务的转型同样影响深远。门诊手术中心的兴起，以及向更早出院和门诊肠外抗生素治疗的转变，正在改变患者流量和药物利用，需要住院团队和社区医疗保健组织之间建立新的合作。监管部门对管理和报告的期望不断变化，更加重视可衡量的指标和专案课责，这使得这些转变变得更加复杂。因此，相关人员面临着这样一种局面：临床有效性、供应可靠性和对管理的遵守程度既决定了病人的治疗结果，也决定了组织的风险。

这些综合因素需要适应性策略，整合新的诊断方法、管理通讯协定和供应链弹性，同时在关键决策点保留临床医师的自主权。积极调整临床路径、采购惯例和监测能力的组织将更有能力管理复杂性，并长期维持治疗方案。

2025年美国关税调整对抗生素供应链、医院采购惯例和临床可近性的预期影响

围绕贸易和关税的政策环境会对抗生素、生产投入以及腹腔感染治疗所必需的医疗用品的成本结构和供应产生重大影响。进口关税和贸易壁垒的变化会改变原料药和成品药的生产经济性，进而影响医院和经销商的筹资策略。实际上，当关税变化扰乱现有的供应链时，采购团队可能会面临供应商选择受限、前置作业时间延长以及某些静脉注射抗生素和肠外製剂采购成本上升的问题。

临床医师和药局负责人必须预见医院处方集和治疗指引变化所带来的副作用。当有采购限製或价格压力时，医院通常会重新评估处方集中的药物，替代临床等效药物或调整管理政策以维持关键库存。这些营运回应需要明确的临床管治，以防止意外后果，例如经验性应用不足或高风险患者替换不当。

此外，製造商和契约製造製造商可以透过转移生产地点、重新设计供应合约以及加快对区域製造业的投资来缓解关税的影响，以应对利润压力。此类策略调整将提升长期韧性，但会带来短期波动。因此，在关税导致供应链中断的情况下，结合采购预测、库存缓衝和持续临床监测的跨职能规划对于维持药品供应和临床完整性至关重要。

跨抗生素类别、感染疾病状况、病原体概况、年龄层和医疗保健环境的细分临床和商业性洞察

细緻的细分视角揭示了治疗方法选择、感染疾病格局、病原体概况、患者人口统计特征和医疗保健环境如何相互交织，共同塑造临床和商业动态。根据抗生素类别，临床医生使用卡巴培南类、头孢菌素类和青霉素类抗生素来涵盖广泛的腹膜内病原体。在卡巴培南类抗生素中，根据病原体疑似情况、组织穿透需求和抗药性模式，使用多利培南、厄他培南、Imipenem/西司他丁和美Meropenem等药物。头孢菌素类药物分为第三代头孢菌素（例如头孢噻肟和头孢曲松）和第四代头孢菌素，每种药物的选择都基于其对特定革兰氏阴性菌的覆盖能力，以及在必要时穿透中枢神经系统的能力。青霉素组合药物，例如Ampicillin/舒巴坦和哌拉西林/他唑巴坦，在社区获得性病菌感染的经验性治疗和许多机构方案中发挥重要作用。

社区型感染和院内获得性感染分为复杂感染和非复杂感染，因此治疗需求也不同。社区型感染通常分为复杂感染和非复杂感染，对于近期无医疗保健暴露的患者，经验性治疗的范围通常较小。相反，无论是在 ICU 还是手术后，院内感染疾病都需要更广泛的经验性治疗方案，因为多重抗药性细菌的风险增加。主导病原体的见解区分了厌氧菌（如脆弱拟桿菌属和梭菌属）、革兰氏阴性菌（如肠桿菌科和铜绿假单胞菌）和革兰氏阳性菌（如肠球菌属和金黄色葡萄球菌），每种细菌都带来不同的经验性和确定性治疗选择和管理挑战。

成人、老年人和儿童的药物动力学和安全性考量各不相同，这些因素会影响剂量、製剂选择和监测。最后，虽然医院分为二级和三级医疗机构，但门诊医疗中心和医院之间最终用户的细分决定了资源的可用性、高级诊断服务的可及性以及源头管理的程序能力。这些相互交叉的细分领域需要量身定制的临床路径、筹资策略和教育计划，以确保每个患者群体都能获得最佳的、针对特定情况的照护。

美洲、中东和非洲以及亚太地区政策的多样性影响着治疗模式、供应链弹性和临床反应

区域差异对临床实务、供应链物流和政策环境有着重大影响，决定医疗服务提供者和卫生系统应对腹腔内感染的方式。在美洲，治疗方案和管理框架越来越强调实证经验性治疗方法选择以及在高级急诊中心整合快速诊断技术，而供应链整合和集团采购组织则影响着处方决策和价格谈判。这些动态正在推动临床领导层和采购部门之间的协调，以确保关键药物的持续供应。

欧洲、中东和非洲地区医疗基础设施、法律规范和抗菌药物抗药性状况各异，导致其优先事项也各有不同。资源丰富的机构专注于快速分子诊断和先进的管理项目，而资源匮乏的机构则优先考虑获得基本抗生素、基本影像和手术能力。政策层面的干预措施和区域合作在支持这一多元化地区的抗菌药物管理和抗药性监测方面发挥更大的作用。

亚太地区临床需求旺盛，技术应用迅速，国内生产能力多样化。虽然区域製造商可以在一定程度上缓解供应中断的影响，但需求压力和韧性趋势需要协调一致的国家管理和采购策略。在所有地区，监管、生产地理和临床实践之间的相互作用将决定短期营运选择以及供应和治疗方法方案的长期韧性。

竞争与合作格局突显抗感染疾病治疗领域的製造能力、诊断创新与策略伙伴关係

腹腔内感染疾病相关治疗方法和服务的竞争格局呈现出老牌製药商、契约製造製造商、诊断创新者和临床服务供应商的混合格局。老牌製药商通常专注于维护可靠的供应线、延长产品生命週期，并透过教育和处方支援来支援倡议计划。契约製造製造商和专业的无菌注射生产设施在确保肠外抗生素的供应方面发挥着至关重要的作用，为策略伙伴关係关係和产能投资创造了机会。

随着快速识别技术和药敏平台直接改变处方行为并缩短最佳治疗时间，诊断公司和医院实验室网路的影响力日益增强。诊断供应商与临床领导者之间的合作可以带来路径层面的改进，从而减少不适当的频谱使用并加快标靶治疗。此外，支持门诊肠外抗生素治疗和出院后监测的服务供应商延长了护理的连续性，使其能够在不牺牲安全性的情况下更早地从住院过渡。

製药商、诊断公司和医疗保健系统之间的策略联盟可以提供将可靠的抗生素供应与诊断管理相结合的综合服务。此类合作也支持透过数据共用、处方优化以及针对处方医生和护理团队的有针对性的教育，共同应对抗生素抗药性问题。

为医疗保健领导者提供可操作的优先建议，以改善临床结果、保留治疗方法选择并增强供应弹性

医疗保健领导者应采取一系列切实可行的优先行动，以提升临床疗效、维持治疗可近性并降低供应风险。首先，协调采购和临床管治，并定期对处方集选择、库存风险和临床可接受的替代治疗方法进行跨职能审查，以确保在供应波动的情况下保持连续性。其次，加速采用快速诊断工具，并将明确的降阶梯方案纳入护理路径，以便在适当的情况下快速确定经验性频谱治疗方案，降低抗药性选择压力，并节省更高级的通讯协定。

第三，我们将扩大门诊肠外抗生素治疗，并加强出院协调，以在确保安全的同时缩短住院时间。第四，我们将实施分级管理指标，考虑感染疾病类型、病原体风险和患者年龄，并将教育和审核工作重点放在临床影响最大的领域。第五，我们将透过多年期合约、尽可能的双重采购以及紧急时应对计画，积极与製造商和委託製造合作，以缓解关税和中断相关的短缺。最后，我们将投资于劳动力发展，使外科团队、加护治疗医师、药剂师和感染疾病专家具备实施快速供应管理、剂量优化和协调追踪的技能。

这些行动共同平衡了当前的营运弹性和长期管理目标，使组织能够提供高品质的护理，同时保持治疗效果。

一种强大的混合方法研究途径，整合了原始临床资讯、操作数据和关于可靠性的严格二次证据

本执行摘要所依据的研究采用混合方法，整合了原始临床数据、机构层面的营运数据和全面的二次研究，以确保得出可靠且基于具体情况的结论。原始数据是透过与外科、重症监护、感染疾病和药学专业的临床医生进行结构化访谈和咨询讨论收集的，并辅以采购和供应链专家的协助，以构建运营蓝图。这些第一手观点有助于制定围绕药物选择、管理实践和供应应急的方案。

二次研究整合了同行评审文献、临床指南、监管文件以及卫生部门公开的监测数据，以基于既定证据得出研究结果。分析了真实世界数据，包括医院用药模式、抗生素使用记录和实验室药敏报告，以识别实践差异和抗药性趋势。在适用的情况下，使用资料三角检验法，根据可观察的营运指标检验定性见解。

分析方法包括比较临床路径图谱绘製、供应中断情境敏感度分析以及相关人员影响评估，以确定建议的优先顺序。在整个过程中，我们专注于资料来源、调查方法透明度和同侪检验，以确保结论反映临床实际情况并具有操作可行性。

整合策略要点，突显临床意义、营运风险和全系统改进的机会

本执行摘要强调了一系列趋同的优先事项：保障有效抗生素的可近性，加速诊断主导医疗服务，以及增强系统层面对供应和政策波动的抵御能力。临床上，快速的供应管理和个人化的抗生素治疗显然可以挽救生命，但要持续实现这一目标，需要在诊断、管理基础设施和跨部门合作方面进行投资。在营运方面，采购和药房负责人必须预测供应链衝击，并保持灵活的策略，在不损害临床标准的前提下保护关键药物。

从策略角度来看，市场环境将有利于那些将诊断与治疗计划相结合，并与製造商和服务供应商建立持久伙伴关係以确保供应可靠性的组织。包括关税调整和不断变化的监管预期在内的政策变化，持续带来风险和机会。最终，将洞察转化为改善患者预后，对于协调临床路径、管理目标和采购惯例至关重要，从而使它们在日常护理和危机应对中相辅相成。

将这些优先事项付诸实施的领导者不仅可以减轻眼前的风险，还可以为维持抗生素有效性和改善腹腔内感染患者预后的更广泛努力做出贡献。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 对抗多重抗药性腹膜内病原体的新型β-内酰胺酶抑制剂组合的需求不断增长
  • 越来越多地采用特异性病原体的快速诊断面板来标靶治疗复杂性腹部脓毒症
  • 增加口服分级抗生素治疗的投资，以减少腹腔内感染疾病的住院时间
  • 新一代头孢菌素-β-内酰胺酶抑制剂组合的出现扩大了对假单胞菌的应用范围
  • 扩大针对腹腔内感染疾病的假单胞菌和肠桿菌科细菌的噬菌体疗法研发管线

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

8. 腹腔内感染疾病市场（依抗生素类型）

  • 卡巴培南类
    • 多利培南
    • 厄他培南
    • Imipenem/西司他丁
    • Meropenem
  • 头孢菌素类
    • 第四代
      • 头孢吡肟
    • 第三代
      • 头孢噻肟
      • 头孢曲松
  • 青霉素
    • Ampicillin/舒巴坦
    • 哌拉西林/他唑巴坦

9. 腹腔内感染疾病市场（依感染类型）

  • 社区收购
    • 复杂的
    • 简单的
  • 院内感染
    • ICU相关
    • 手术后

第十章腹腔内感染疾病市场（依病原体类型）

  • 厌氧
    • 脆弱拟桿菌
    • 梭菌
  • 革兰氏阴性菌
    • 肠桿菌科
    • 铜绿假单胞菌
  • 革兰氏阳性
    • 肠球菌
    • 金黄色葡萄球菌

第 11 章。按患者年龄组别分類的腹腔内感染疾病市场

  • 成人
  • 老年人
  • 孩子们

第 12 章。腹腔内感染疾病市场（按最终用户）

  • 门诊治疗中心
  • 医院
    • 二级护理
    • 三级护理

13. 腹腔内感染疾病市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第 14 章腹腔内感染疾病市场（依类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 腹腔内感染疾病市场（依国家）

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Pfizer Inc.
    • Sandoz International GmbH
    • Teva Pharmaceutical Industries Ltd.
    • Merck & Co., Inc.
    • Fresenius Kabi AG
    • Hikma Pharmaceuticals PLC
    • Allergan plc
    • GlaxoSmithKline plc
    • Cipla Limited
    • Lupin Limited
Product Code: MRR-43127F7279D5

The Intra-abdominal Infections Market is projected to grow by USD 49.70 billion at a CAGR of 9.20% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 24.57 billion
Estimated Year [2025] USD 26.86 billion
Forecast Year [2032] USD 49.70 billion
CAGR (%) 9.20%

Intra-abdominal infections represent a heterogeneous group of conditions that span simple localized inflammatory processes to complex, life-threatening polymicrobial sepsis. Clinicians confront a mix of community-acquired and hospital-acquired presentations that vary by source, host factors, and microbiology. As a result, early recognition and rapid source control remain the cornerstones of effective management, while antimicrobial selection must balance empiric breadth with de-escalation guided by culture and sensitivity data.

Diagnostic complexity stems from overlapping clinical presentations, variable culture yields, and evolving resistance patterns. Imaging, surgical assessment, and peritoneal cultures are critical, yet each has limitations that influence therapeutic timing. Concurrently, antimicrobial resistance among key pathogens has altered empirical therapy algorithms, prompting greater reliance on higher-tier agents and combination regimens in severe cases. These changes amplify the need for coordinated antimicrobial stewardship, multidisciplinary care pathways, and robust hospital surveillance to preserve therapeutic options and optimize outcomes.

Stakeholders across clinical, operational, and commercial domains must therefore align on priorities that include timely diagnostics, stewardship integration, and supply chain continuity. By understanding the clinical nuances and system pressures that drive treatment decisions, leaders can better design interventions that reduce morbidity, shorten hospital stays, and limit the collateral harm of unnecessary broad-spectrum antibiotic exposure.

Rapid Transformations Reshaping Clinical Practice, Diagnostics, and Supply Dynamics in Intra-abdominal Infection Management

The landscape of intra-abdominal infection management is undergoing rapid and consequential shifts driven by antimicrobial resistance, technological advances, and changes in care delivery models. Resistance trends are reshaping empiric prescribing patterns and elevating the clinical and economic value of agents with retained activity against multidrug-resistant Gram-negative organisms. Simultaneously, innovations in rapid diagnostics and molecular pathogen detection are beginning to shorten the interval between presentation and targeted therapy, enabling faster de-escalation when appropriate and reducing unnecessary exposure to broad-spectrum agents.

Care delivery transformations are equally impactful. Growth in ambulatory surgical centers and shifts toward earlier discharge and outpatient parenteral antimicrobial therapy have altered patient flows and medication utilization, requiring new coordination between inpatient teams and community providers. These transitions are compounded by evolving regulatory expectations for stewardship and reporting, which place a premium on measurable metrics and program accountability. As a result, stakeholders face a landscape where clinical efficacy, supply reliability, and stewardship compliance converge to determine both patient outcomes and organizational risk.

Taken together, these forces demand adaptive strategies that integrate novel diagnostics, stewardship protocols, and supply chain resilience while maintaining clinician autonomy in critical decision moments. Organizations that proactively align clinical pathways, procurement practices, and surveillance capabilities will be better positioned to manage complexity and sustain therapeutic options over the long term.

Anticipated Effects of United States Tariff Adjustments on Antibiotic Supply Chains, Hospital Procurement Practices, and Clinical Access in 2025

The policy environment surrounding trade and tariffs can materially influence the cost structure and availability of antimicrobial agents, manufacturing inputs, and medical supplies integral to intra-abdominal infection care. Changes to import duties and trade barriers alter manufacturing economics for active pharmaceutical ingredients and finished dosage forms, which in turn affect procurement strategies for hospitals and distributors. In practical terms, procurement teams may experience narrower supplier options, increased lead times, and higher acquisition costs for select intravenous antibiotics and parenteral formulations when tariffs disrupt established supply chains.

Clinicians and pharmacy leaders should anticipate secondary effects that manifest as alterations in hospital formularies and therapeutic guidelines. When sourcing constraints or price pressures exist, hospitals commonly reassess formulary inclusions and may substitute clinically equivalent agents or adjust stewardship policies to preserve critical stock. These operational responses require clear clinical governance to prevent unintended consequences such as suboptimal empiric coverage or inappropriate substitution in high-risk patients.

Moreover, manufacturers and contract manufacturers may respond to tariff-driven margin pressures by relocating production, redesigning supply agreements, or accelerating investments in regional manufacturing to mitigate exposure. Such strategic adaptations can improve long-term resilience but create short-term volatility. Therefore, cross-functional planning that combines procurement forecasting, inventory buffering, and continual clinical oversight is essential to maintain access and clinical integrity in the face of tariff-induced supply chain disruption.

Segment-Level Clinical and Commercial Insights Spanning Antibiotic Classes, Infection Presentations, Pathogen Profiles, Age Cohorts, and Healthcare Settings

A nuanced segmentation lens reveals how therapeutic choices, infection contexts, pathogen profiles, patient demographics, and care settings intersect to shape clinical and commercial dynamics. By antibiotic class, clinicians rely on carbapenems, cephalosporins, and penicillins to cover the broad spectrum of intra-abdominal pathogens. Within carbapenems, agents such as doripenem, ertapenem, imipenem/cilastatin, and meropenem are deployed based on pathogen suspicion, tissue penetration requirements, and resistance patterns. Cephalosporin use differentiates between third-generation options like cefotaxime and ceftriaxone and fourth-generation cefepime, each selected for specific Gram-negative coverage and central nervous system penetration when indicated. Penicillin-based combinations, including ampicillin/sulbactam and piperacillin/tazobactam, retain an important role for community-acquired polymicrobial infections and as empiric therapy in many institutional protocols.

Infection type segmentation between community-acquired and hospital-acquired presentations changes therapeutic imperatives. Community-acquired cases, subdivided into complicated and uncomplicated forms, often permit narrower empiric coverage when patients present without recent healthcare exposure. Conversely, hospital-acquired infections, whether associated with ICU care or post-surgical settings, demand broader empiric regimens because of increased risk of multidrug-resistant organisms. Pathogen-driven insight distinguishes anaerobic organisms such as Bacteroides fragilis and Clostridium species from Gram-negative pathogens including Enterobacteriaceae and Pseudomonas aeruginosa, and from Gram-positive agents like Enterococcus species and Staphylococcus aureus, each of which drives different empiric and definitive therapy choices and stewardship challenges.

Patient age group further modulates therapeutic decisions, as adult, geriatric, and pediatric populations present distinct pharmacokinetic and safety considerations that affect dosing, formulation selection, and monitoring. Finally, end user segmentation between ambulatory care centres and hospitals, with hospitals split into secondary and tertiary care, determines resource availability, access to advanced diagnostics, and procedural capabilities for source control. Collectively, these intersecting segments demand tailored clinical pathways, procurement strategies, and education programs to ensure that each patient cohort receives optimal, context-appropriate care.

Regional Treatment Patterns, Supply Chain Resilience, and Policy Variations Shaping Clinical Responses Across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional variation exerts a profound influence on clinical practice, supply chain logistics, and policy environments, shaping how providers and health systems approach intra-abdominal infections. In the Americas, treatment protocols and stewardship frameworks increasingly emphasize evidence-based empiric selection and the integration of rapid diagnostics in high-acuity centers, while supply chain consolidation and group purchasing organizations influence formulary decisions and pricing negotiations. These dynamics encourage coordination between clinical leaders and procurement to ensure consistent access to critical agents.

In Europe, Middle East & Africa, heterogeneity in healthcare infrastructure, regulatory oversight, and antimicrobial resistance profiles creates divergent priorities. High-resource centers may focus on rapid molecular diagnostics and advanced stewardship programs, whereas resource-constrained settings prioritize access to essential antibiotics, basic imaging, and surgical capacity. Policy-level interventions and regional collaborations play a larger role in supporting antimicrobial stewardship and addressing resistance surveillance in this diverse region.

Asia-Pacific presents a combination of high-volume clinical demand, rapid technological adoption, and varied domestic manufacturing capacity. Regional manufacturers can mitigate some supply disruptions, but demand pressures and resistance trends necessitate coordinated national strategies for stewardship and procurement. Across all regions, the interplay between regulation, manufacturing geography, and clinical practice determines both short-term operational choices and long-term resilience of supply and therapeutic options.

Competitive and Collaborative Company Landscape Highlighting Manufacturing Capacity, Diagnostic Innovation, and Strategic Partnerships in Anti-infective Care

The competitive landscape for therapies and services relevant to intra-abdominal infections is characterized by a mix of established pharmaceutical manufacturers, contract producers, diagnostic innovators, and clinical service providers. Established drug producers often focus on maintaining reliable supply lines, extending product lifecycles, and supporting stewardship initiatives through education and formulary support. Contract manufacturers and specialized sterile injectable plants play a pivotal role in ensuring availability of parenteral antibiotics, creating opportunities for strategic partnerships and capacity investments.

Diagnostic companies and hospital laboratory networks are increasingly influential, as rapid identification technologies and susceptibility platforms directly change prescribing behavior and reduce time to optimal therapy. Collaboration between diagnostic vendors and clinical leaders can yield pathway-level improvements that reduce inappropriate broad-spectrum use and speed targeted therapy. Additionally, service providers that support outpatient parenteral antimicrobial therapy and post-discharge monitoring are expanding the continuum of care, enabling earlier transition from inpatient settings without sacrificing safety.

Strategic alliances between pharmaceutical manufacturers, diagnostic firms, and healthcare systems can create integrated offerings that pair reliable antimicrobial supply with diagnostic stewardship. Such collaboration also supports joint efforts to address antimicrobial resistance through data sharing, formulary optimization, and targeted education for prescribers and care teams.

Actionable and Prioritized Recommendations for Healthcare Leaders to Improve Clinical Outcomes, Preserve Therapeutic Options, and Strengthen Supply Resilience

Healthcare leaders should adopt a set of practical, prioritized actions to strengthen clinical outcomes, maintain therapeutic access, and mitigate supply risks. First, align procurement and clinical governance by instituting regular cross-functional reviews of formulary choices, inventory exposure, and clinically acceptable therapeutic alternatives to ensure continuity in the face of supply variability. Second, accelerate adoption of rapid diagnostic tools and embed explicit de-escalation protocols into care pathways so that empiric broad-spectrum therapy is narrowed promptly when appropriate, reducing resistance selection pressure and conserving higher-tier agents.

Third, expand outpatient parenteral antimicrobial therapy frameworks and strengthen discharge coordination to reduce inpatient length of stay while maintaining safety. Fourth, implement tiered stewardship metrics that account for infection type, pathogen risk, and patient age to target education and audit efforts where they will have the greatest clinical impact. Fifth, engage manufacturers and contract manufacturers proactively through multi-year agreements, dual-sourcing where feasible, and contingency planning to alleviate tariff- or disruption-related scarcity. Finally, invest in workforce training that equips surgical teams, intensivists, pharmacists, and infectious disease specialists with the skills to execute rapid source control, optimized dosing, and coordinated follow-up care.

Taken together, these actions balance immediate operational resilience with long-term stewardship objectives, positioning organizations to deliver high-quality care while preserving therapeutic effectiveness.

Robust Mixed Methods Research Approach Integrating Primary Clinical Input, Real-world Operational Data, and Rigorous Secondary Evidence for Reliability

The research underpinning this executive summary uses a mixed-methods approach that integrates primary clinical inputs, facility-level operational data, and comprehensive secondary research to ensure robust, context-sensitive conclusions. Primary inputs were gathered through structured interviews and advisory discussions with clinicians across surgical, critical care, infectious disease, and pharmacy disciplines, complemented by procurement and supply chain professionals to capture operational realities. These firsthand perspectives informed scenario building around drug selection, stewardship practices, and supply contingencies.

Secondary research synthesized peer-reviewed literature, clinical guidelines, regulatory documents, and publicly available surveillance data from health authorities to ground findings in established evidence. Real-world data sources such as hospital utilization patterns, antimicrobial consumption records, and laboratory susceptibility reports were analyzed to identify practice variation and resistance trends. Where applicable, data triangulation validated qualitative insights against observable operational metrics.

Analytical methods included comparative clinical pathway mapping, sensitivity analysis of supply disruption scenarios, and stakeholder impact assessments to prioritize recommendations. Throughout the process, attention to data provenance, methodological transparency, and expert validation ensured that conclusions reflect clinical reality and operational feasibility.

Synthesis of Strategic Takeaways Emphasizing Clinical Imperatives, Operational Risks, and Opportunities for System-wide Improvement

This executive synthesis highlights a set of converging priorities: protect access to effective antimicrobials, accelerate diagnostic-driven therapy, and reinforce system-level resilience against supply and policy volatility. Clinically, the imperative is clear-prompt source control and tailored antimicrobial therapy save lives, but achieving this consistently requires investments in diagnostics, stewardship infrastructure, and cross-disciplinary coordination. Operationally, procurement and pharmacy leaders must anticipate supply chain shocks and maintain flexible strategies that safeguard critical agents without compromising clinical standards.

Strategically, the market environment rewards organizations that integrate diagnostics with therapeutic planning and that form durable partnerships with manufacturers and service providers to ensure supply reliability. Policy changes, including tariff adjustments and evolving regulatory expectations, will continue to create both risks and opportunities; responsive systems will be those that combine clinical rigor with agile contracting and contingency planning. Ultimately, translating insight into improved patient outcomes depends on aligning clinical pathways, stewardship goals, and procurement practices so that each reinforces the others in routine care and crisis response.

Leaders who operationalize these priorities will not only mitigate immediate risks but also contribute to broader efforts to preserve antimicrobial effectiveness and improve outcomes for patients with intra-abdominal infections.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rising demand for novel B-lactamase inhibitor combinations to combat multidrug-resistant intra-abdominal pathogens
  • 5.2. Increasing adoption of pathogen-specific rapid diagnostic panels for targeted therapy in complex abdominal sepsis
  • 5.3. Growing investment in oral step-down antibiotic regimens to reduce hospital length of stay in intra-abdominal infections
  • 5.4. Emergence of next-generation cephalosporin-B-lactamase inhibitor combinations offering expanded Pseudomonas coverage in intra-abdominal infections
  • 5.5. Expanding pipeline of bacteriophage therapies targeting Pseudomonas and Enterobacteriaceae in intra-abdominal infections

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Intra-abdominal Infections Market, by Antibiotic Class

  • 8.1. Carbapenems
    • 8.1.1. Doripenem
    • 8.1.2. Ertapenem
    • 8.1.3. Imipenem/Cilastatin
    • 8.1.4. Meropenem
  • 8.2. Cephalosporins
    • 8.2.1. Fourth Generation
      • 8.2.1.1. Cefepime
    • 8.2.2. Third Generation
      • 8.2.2.1. Cefotaxime
      • 8.2.2.2. Ceftriaxone
  • 8.3. Penicillins
    • 8.3.1. Ampicillin/Sulbactam
    • 8.3.2. Piperacillin/Tazobactam

9. Intra-abdominal Infections Market, by Infection Type

  • 9.1. Community Acquired
    • 9.1.1. Complicated
    • 9.1.2. Uncomplicated
  • 9.2. Hospital Acquired
    • 9.2.1. ICU Associated
    • 9.2.2. Post Surgical

10. Intra-abdominal Infections Market, by Pathogen Type

  • 10.1. Anaerobic
    • 10.1.1. Bacteroides Fragilis
    • 10.1.2. Clostridium Species
  • 10.2. Gram Negative
    • 10.2.1. Enterobacteriaceae
    • 10.2.2. Pseudomonas Aeruginosa
  • 10.3. Gram Positive
    • 10.3.1. Enterococcus Species
    • 10.3.2. Staphylococcus Aureus

11. Intra-abdominal Infections Market, by Patient Age Group

  • 11.1. Adult
  • 11.2. Geriatric
  • 11.3. Pediatric

12. Intra-abdominal Infections Market, by End User

  • 12.1. Ambulatory Care Centres
  • 12.2. Hospitals
    • 12.2.1. Secondary Care
    • 12.2.2. Tertiary Care

13. Intra-abdominal Infections Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Intra-abdominal Infections Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Intra-abdominal Infections Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Pfizer Inc.
    • 16.3.2. Sandoz International GmbH
    • 16.3.3. Teva Pharmaceutical Industries Ltd.
    • 16.3.4. Merck & Co., Inc.
    • 16.3.5. Fresenius Kabi AG
    • 16.3.6. Hikma Pharmaceuticals PLC
    • 16.3.7. Allergan plc
    • 16.3.8. GlaxoSmithKline plc
    • 16.3.9. Cipla Limited
    • 16.3.10. Lupin Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANTIBIOTIC CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANTIBIOTIC CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY INFECTION TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY INFECTION TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PATHOGEN TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PATHOGEN TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. INTRA-ABDOMINAL INFECTIONS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. INTRA-ABDOMINAL INFECTIONS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. INTRA-ABDOMINAL INFECTIONS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANTIBIOTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANTIBIOTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CARBAPENEMS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CARBAPENEMS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CARBAPENEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CARBAPENEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CARBAPENEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CARBAPENEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CARBAPENEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CARBAPENEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DORIPENEM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DORIPENEM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DORIPENEM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DORIPENEM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DORIPENEM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DORIPENEM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ERTAPENEM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ERTAPENEM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ERTAPENEM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ERTAPENEM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ERTAPENEM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ERTAPENEM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY IMIPENEM/CILASTATIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY IMIPENEM/CILASTATIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY IMIPENEM/CILASTATIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY IMIPENEM/CILASTATIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY IMIPENEM/CILASTATIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY IMIPENEM/CILASTATIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY MEROPENEM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY MEROPENEM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY MEROPENEM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY MEROPENEM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY MEROPENEM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY MEROPENEM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEPHALOSPORINS, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEPHALOSPORINS, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEPHALOSPORINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEPHALOSPORINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEPHALOSPORINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEPHALOSPORINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEPHALOSPORINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEPHALOSPORINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY FOURTH GENERATION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY FOURTH GENERATION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY FOURTH GENERATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY FOURTH GENERATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY FOURTH GENERATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY FOURTH GENERATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY FOURTH GENERATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY FOURTH GENERATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEFEPIME, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEFEPIME, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEFEPIME, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEFEPIME, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEFEPIME, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEFEPIME, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY THIRD GENERATION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY THIRD GENERATION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY THIRD GENERATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY THIRD GENERATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY THIRD GENERATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY THIRD GENERATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY THIRD GENERATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY THIRD GENERATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEFOTAXIME, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEFOTAXIME, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEFOTAXIME, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEFOTAXIME, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEFOTAXIME, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEFOTAXIME, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEFTRIAXONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEFTRIAXONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEFTRIAXONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEFTRIAXONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEFTRIAXONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEFTRIAXONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PENICILLINS, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PENICILLINS, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PENICILLINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PENICILLINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PENICILLINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PENICILLINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PENICILLINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PENICILLINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY AMPICILLIN/SULBACTAM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY AMPICILLIN/SULBACTAM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY AMPICILLIN/SULBACTAM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY AMPICILLIN/SULBACTAM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY AMPICILLIN/SULBACTAM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY AMPICILLIN/SULBACTAM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PIPERACILLIN/TAZOBACTAM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PIPERACILLIN/TAZOBACTAM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PIPERACILLIN/TAZOBACTAM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PIPERACILLIN/TAZOBACTAM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PIPERACILLIN/TAZOBACTAM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PIPERACILLIN/TAZOBACTAM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY INFECTION TYPE, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COMMUNITY ACQUIRED, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COMMUNITY ACQUIRED, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COMMUNITY ACQUIRED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COMMUNITY ACQUIRED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COMMUNITY ACQUIRED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COMMUNITY ACQUIRED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COMMUNITY ACQUIRED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COMMUNITY ACQUIRED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COMPLICATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COMPLICATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COMPLICATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COMPLICATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COMPLICATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COMPLICATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY UNCOMPLICATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY UNCOMPLICATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY UNCOMPLICATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY UNCOMPLICATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY UNCOMPLICATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY UNCOMPLICATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITAL ACQUIRED, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITAL ACQUIRED, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITAL ACQUIRED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITAL ACQUIRED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITAL ACQUIRED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITAL ACQUIRED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITAL ACQUIRED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITAL ACQUIRED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ICU ASSOCIATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ICU ASSOCIATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ICU ASSOCIATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ICU ASSOCIATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ICU ASSOCIATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ICU ASSOCIATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY POST SURGICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY POST SURGICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY POST SURGICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY POST SURGICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY POST SURGICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY POST SURGICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PATHOGEN TYPE, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANAEROBIC, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANAEROBIC, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANAEROBIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANAEROBIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANAEROBIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANAEROBIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANAEROBIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANAEROBIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY BACTEROIDES FRAGILIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY BACTEROIDES FRAGILIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY BACTEROIDES FRAGILIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY BACTEROIDES FRAGILIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY BACTEROIDES FRAGILIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY BACTEROIDES FRAGILIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CLOSTRIDIUM SPECIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CLOSTRIDIUM SPECIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CLOSTRIDIUM SPECIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CLOSTRIDIUM SPECIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CLOSTRIDIUM SPECIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CLOSTRIDIUM SPECIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM NEGATIVE, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM NEGATIVE, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM NEGATIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM NEGATIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM NEGATIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM NEGATIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM NEGATIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM NEGATIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ENTEROBACTERIACEAE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ENTEROBACTERIACEAE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ENTEROBACTERIACEAE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ENTEROBACTERIACEAE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ENTEROBACTERIACEAE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ENTEROBACTERIACEAE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PSEUDOMONAS AERUGINOSA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PSEUDOMONAS AERUGINOSA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PSEUDOMONAS AERUGINOSA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PSEUDOMONAS AERUGINOSA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PSEUDOMONAS AERUGINOSA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PSEUDOMONAS AERUGINOSA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM POSITIVE, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM POSITIVE, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM POSITIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM POSITIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM POSITIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM POSITIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM POSITIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM POSITIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ENTEROCOCCUS SPECIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ENTEROCOCCUS SPECIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ENTEROCOCCUS SPECIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ENTEROCOCCUS SPECIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ENTEROCOCCUS SPECIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ENTEROCOCCUS SPECIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY STAPHYLOCOCCUS AUREUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY STAPHYLOCOCCUS AUREUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY STAPHYLOCOCCUS AUREUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY STAPHYLOCOCCUS AUREUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY STAPHYLOCOCCUS AUREUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY STAPHYLOCOCCUS AUREUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GERIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY AMBULATORY CARE CENTRES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY AMBULATORY CARE CENTRES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY AMBULATORY CARE CENTRES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY AMBULATORY CARE CENTRES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY AMBULATORY CARE CENTRES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY AMBULATORY CARE CENTRES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY SECONDARY CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY SECONDARY CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY SECONDARY CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY SECONDARY CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY SECONDARY CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY SECONDARY CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY TERTIARY CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY TERTIARY CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY TERTIARY CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY TERTIARY CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY TERTIARY CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY TERTIARY CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 255. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 256. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 257. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANTIBIOTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 258. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANTIBIOTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 259. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CARBAPENEMS, 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CARBAPENEMS, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEPHALOSPORINS, 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEPHALOSPORINS, 2025-2032 (USD MILLION)
  • TABLE 263. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY FOURTH GENERATION, 2018-2024 (USD MILLION)
  • TABLE 264. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY FOURTH GENERATION, 2025-2032 (USD MILLION)
  • TABLE 265. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY THIRD GENERATION, 2018-2024 (USD MILLION)
  • TABLE 266. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY THIRD GENERATION, 2025-2032 (USD MILLION)
  • TABLE 267. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PENICILLINS, 2018-2024 (USD MILLION)
  • TABLE 268. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PENICILLINS, 2025-2032 (USD MILLION)
  • TABLE 269. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 270. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY INFECTION TYPE, 2025-2032 (USD MILLION)
  • TABLE 271. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COMMUNITY ACQUIRED, 2018-2024 (USD MILLION)
  • TABLE 272. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COMMUNITY ACQUIRED, 2025-2032 (USD MILLION)
  • TABLE 273. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITAL ACQUIRED, 2018-2024 (USD MILLION)
  • TABLE 274. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITAL ACQUIRED, 2025-2032 (USD MILLION)
  • TABLE 275. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PATHOGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 276. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PATHOGEN TYPE, 2025-2032 (USD MILLION)
  • TABLE 277. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANAEROBIC, 2018-2024 (USD MILLION)
  • TABLE 278. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANAEROBIC, 2025-2032 (USD MILLION)
  • TABLE 279. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM NEGATIVE, 2018-2024 (USD MILLION)
  • TABLE 280. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM NEGATIVE, 2025-2032 (USD MILLION)
  • TABLE 281. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM POSITIVE, 2018-2024 (USD MILLION)
  • TABLE 282. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY GRAM POSITIVE, 2025-2032 (USD MILLION)
  • TABLE 283. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 284. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 285. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 286. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 287. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 288. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 289. NORTH AMERICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. NORTH AMERICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. NORTH AMERICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANTIBIOTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 292. NORTH AMERICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ANTIBIOTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 293. NORTH AMERICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CARBAPENEMS, 2018-2024 (USD MILLION)
  • TABLE 294. NORTH AMERICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CARBAPENEMS, 2025-2032 (USD MILLION)
  • TABLE 295. NORTH AMERICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEPHALOSPORINS, 2018-2024 (USD MILLION)
  • TABLE 296. NORTH AMERICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEPHALOSPORINS, 2025-2032 (USD MILLION)
  • TABLE 297. NORTH AMERICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY FOURTH GENERATION, 2018-2024 (USD MILLION)
  • TABLE 298. NORTH AMERICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY FOURTH GENERATION, 2025-2032 (USD MILLION)
  • TABLE 299. NORTH AMERICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY THIRD GENERATION, 2018-2024 (USD MILLION)
  • TABLE 300. NORTH AMERICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY THIRD GENERATION, 2025-2032 (USD MILLION)
  • TABLE 301. NORTH AMERICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PENICILLINS, 2018-2024 (USD MILLION)
  • TABLE 302. NORTH AMERICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY PENICILLINS, 2